Artios

Artios is dedicated to revolutionizing cancer treatment through pioneering research in DNA Damage Response (DDR). By leveraging the DcoDeR platform, Artios is committed to discovering and developing innovative medicines that target DDR pathways, crucial for cancer cell survival. The company's extensive pipeline focuses on addressing unmet needs in solid tumor indications, featuring the ATR inhibitor, ART0380, and the Polθ inhibitor ART6043, both developed for monotherapy and combination treatments.

Artios operates from two key locations: the primary address at The Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, GB, and a secondary location at 215 Park Avenue South, New York, New York 10003, US. Through strategic partnerships with Merck KGaA, Novartis, and research collaborations with esteemed institutions such as Cancer Research UK and The Institute of Cancer Research, Artios is at the forefront of DDR drug discovery.

With a focus on innovation and a commitment to advancing cancer therapeutics, Artios continues to expand its research and development efforts. We invite the management team at Artios to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.